 | | Vol. 10.11 – 5 April, 2024 |
| |
|
|
| Researchers identified that MEX3A, frequently upregulated in colorectal cancer tissues, predicted poorer patient survival.
[Signal Transduction And Targeted Therapy] |
|
|
|
 | | PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Investigators reported a self-powered electronic bandage made from soft and biodegradable materials that could accelerate wound healing in the intestine.
[Nature Electronics] |
|
|
|
| Researchers reported that colorectal cancer cells that were insensitive to single-agent enhancer of zeste homolog 2 (EZH2) inhibition became sensitive as compensatory lysine-27 trimethylation on histone H3 mediated silencing emerged upon DNA methyltransferase inhibitor treatment.
[Science Advances] |
|
|
|
| Scientists evidenced the role of ubiquitin-specific peptidase 26 (USP26) in promoting colorectal cancer tumorigenesis in a parkin RBR E3 ubiquitin-protein ligase (PRKN) protein-dependent manner.
[Oncogene] |
|
|
|
| The authors investigated the biological effects of lncRNA WAP four-disulfide core domain 21 pseudogene (WFDC21P) in gastric cancer, and reported that WFDC21P downregulation resulted in suppressed proliferation, tumorigenesis, migration, invasion, and promoted apoptosis.
[Cancer Cell International] |
|
|
|
| Analogs of echinomycin, a cyclic peptide natural product with potent toxicity to several human cancer cell lines, were synthesized, and their biological activities against human colon cancer cells were investigated.
[Scientific Reports] |
|
|
|
|
| Scientists provide insights into the clinico-biological characteristics of the consensus molecular subtype (CMS) CMS4 colorectal cancer subgroup, the molecular pathways driving this subtype, and available diagnostic options.
[Clinical Cancer Research] |
|
|
|
|
| Bausch Health Canada, Inc. announced the first public drug plan listings for PrUCERIS® (budesonide) aerosol foam to treat mild to moderate distal ulcerative colitis in adults.
[Bausch Health Canada, Inc.] |
|
|
|
| Dr. Patrick Varley was awarded a one-year, $60,000 Institutional Research Grant that provides funding for a pilot study evaluating the effect of residential neighborhood disparities on colorectal cancer outcomes within the Veterans Health Administration system.
[University of Wisconsin-Madison] |
|
|
|
|
|
|
|
| | Duke University School of Medicine – Durham, North Carolina, United States |
|
|
|
| | Baylor College of Medicine – Houston, Texas, United States |
|
|
|
| | University of Colorado – Aurora, Colorado, United States |
|
|
|
| | University of Kentucky – Lexington, Kentucky, United States |
|
|
|
| | University of Montpellier – Montpellier, France |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
